RMD Stock Risk & Deep Value Analysis
Resmed Inc
Healthcare • Medical Instruments & Supplies
DVR Score
out of 10
What You Need to Know About RMD Stock
We analyzed Resmed Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran RMD through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
RMD Risk Analysis & Red Flags
What Could Go Wrong
The primary risk for RMD is a slowdown in its core market growth coupled with intensified competition, particularly from new technologies or more aggressive pricing strategies from rivals. This could lead to revenue growth deceleration below current expectations and a compression of its valuation multiple.
Risk Matrix
Overall
Moderate
Financial
Low
Market
Low
Competitive
Medium
Execution
Medium
Regulatory
Medium
Red Flags
- ⚠
CFO selling shares, even if pre-planned (not a strong vote of confidence for hyper-growth)
- ⚠
Reported revenue growth slower than peers in Q2 FY2026 indicates potential market share erosion or competitive pressures.
Upcoming Risk Events
- 📅
Increased competitive pressure from existing or new entrants
- 📅
Changes in healthcare reimbursement policies or regulatory landscape
- 📅
Supply chain disruptions impacting device manufacturing
When to Reconsider
- 🚪
Exit if quarterly revenue growth consistently falls below 5% YoY for two consecutive quarters.
- 🚪
Sell if significant market share is demonstrably lost to a competitor in key product categories.
- 🚪
Exit if the forward P/E multiple contracts significantly without a clear fundamental reason.
Unlock RMD Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Resmed Inc (RMD) Do?
Market Cap
$32.65B
Sector
Healthcare
Industry
Medical Instruments & Supplies
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Visit Resmed Inc WebsiteInvestment Thesis
ResMed offers a stable investment opportunity as a market leader in essential and growing healthcare sectors. Its strong financial health, consistent profitability, and established competitive advantages make it a reliable choice for long-term investors seeking moderate, compounding growth rather than hyper-growth. Continued innovation in connected health and benefiting from demographic tailwinds will underpin its steady performance.
Is RMD Stock Undervalued?
Unlock the full AI analysis for RMD
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
RMD Price Targets & Strategy
12-Month Target
$295.23
Bull Case
$330.00
Bear Case
$200.00
Valuation Basis
Based on 26.89x forward P/E applied to $10.98 est. FY26 EPS (from analyst median target)
Entry Strategy
Dollar-cost average on dips towards $210-$220, focusing on maintaining position below the analyst median target entry point.
Exit Strategy
Take profits at $295-$300 (analyst median target), consider a stop loss if consistent trading below $200 occurs.
Portfolio Allocation
3-5% for moderate risk tolerance
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is RMD Financially Healthy?
Valuation
P/E Ratio
21.90
Forward P/E
22.00
EV/EBITDA
15.50
PEG Ratio
1.59
Price/Book
5.10
Price/Sales
6.00
Balance Sheet
Current Ratio
3.06
Quick Ratio
2.32
Debt/Equity
0.06
Cash Flow
EBITDA
$2.10B
Other
Beta (Volatility)
0.93
Dividend Yield
1.00%
Does RMD Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable
Moat Sources
4 Identified
ResMed's strong brand, extensive patent portfolio for its devices and masks, and its integrated digital health platform create a sticky ecosystem that makes it challenging for patients and providers to switch to alternatives easily. Its scale in manufacturing and distribution also provides cost advantages.
Moat Erosion Risks
- •Introduction of radically new, more effective, or non-device-based therapies for sleep apnea or COPD.
- •Aggressive pricing strategies or superior product innovation from well-funded competitors.
RMD Competitive Moat Analysis
Sign up to see competitive advantages
RMD Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral (Consistent performance in an established sector typically doesn't generate extreme social media buzz.)
Institutional Sentiment
Neutral/Positive (Analyst consensus is 'Moderate Buy' with a 33.9% upside, indicating confidence but not exceptional bullishness for hyper-growth.)
Insider Activity (Form 4)
CFO Brett Sandercock sold 1,000 shares ($224,310) on April 1, 2026, under a Rule 10b5-1 plan. Affiliates proposed further sales in Jan-Mar 2026. This indicates planned selling rather than new, aggressive buying.
Options Flow
Normal options activity (No specific unusual options activity reported in real-time intelligence.)
Earnings Intelligence
Next Earnings
2026-04-30
Surprise Probability
Medium
Historical Earnings Pattern
RMD has a history of meeting or slightly beating analyst estimates (e.g., Q2 FY2026). Stock reactions are typically moderate unless guidance significantly deviates from expectations.
Key Metrics to Watch
Competitive Position
Top Competitor
Philips Respironics
Market Share Trend
Stable in core segments, but slower revenue growth than peers suggests either market maturation or subtle market share shifts.
Valuation vs Peers
Likely trades at a premium due to market leadership, strong profitability, and consistent cash generation, despite reporting slower revenue growth than some peers in the last quarter.
Competitive Advantages
- •Strong brand recognition and reputation in sleep and respiratory care
- •Extensive intellectual property portfolio and R&D capabilities
- •Global distribution network and established clinician relationships
- •Integrated digital health ecosystem (connected devices, software)
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive RMD Stock Higher?
Near-Term (0-6 months)
- •Q3 FY2026 Earnings Announcement (April 30, 2026)
- •Continued adoption and expansion of connected health solutions
Medium-Term (6-18 months)
- •Potential new product launches or feature enhancements in respiratory care
- •Expansion into emerging markets or underpenetrated segments
Long-Term (18+ months)
- •Leveraging AI/ML for personalized therapy and patient engagement
- •Demographic tailwinds (aging population, rising prevalence of sleep apnea)
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for RMD?
- ✓
Acceleration in adoption rates of its cloud-connected devices and software solutions.
- ✓
Successful penetration into new, high-growth respiratory care segments.
- ✓
Sustained expansion of gross and net profit margins.
Bull Case Analysis
See what could go right with Premium
Competing with RMD
See how Resmed Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Resmed Inc RMD | $32.6B | 0.1 | 21.9 | $5.1B | 0.0% | 11.0% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $154.6B | 0.2 | 19.9 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Resmed Inc Makes Money
ResMed Inc. designs, manufactures, and markets medical devices and software solutions for the diagnosis, treatment, and management of sleep-disordered breathing (like sleep apnea) and other respiratory conditions (like COPD). The company generates revenue primarily through the sale of its masks, accessories, and flow generators (CPAP, BiPAP devices), complemented by growing subscription revenue from its digital health software platforms that allow remote patient monitoring and data management for healthcare providers.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Resmed Inc (RMD)?
As of April 6, 2026, Resmed Inc has a DVR Score of 0.1 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Resmed Inc?
Resmed Inc's market capitalization is approximately $32.6B. The company operates in the Healthcare sector within the Medical Instruments & Supplies industry.
What ticker symbol does Resmed Inc use?
RMD is the ticker symbol for Resmed Inc. The company trades on the NYQ.
What is the risk level for RMD stock?
Our analysis rates Resmed Inc's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of RMD?
Resmed Inc currently has a price-to-earnings (P/E) ratio of 21.9. This is in line with broader market averages.
Does Resmed Inc pay a dividend?
Yes, Resmed Inc pays a dividend with a current yield of approximately 1.00%.
Is Resmed Inc's revenue growing?
Resmed Inc has reported revenue growth of 11.0%. The company is showing strong top-line momentum.
Is RMD stock profitable?
Resmed Inc has a profit margin of 0.0%. The company is currently unprofitable.
How often is the RMD DVR analysis updated?
Our AI-powered analysis of Resmed Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 6, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for RMD (Resmed Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.